How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)779-781
Number of pages3
JournalJournal of the National Cancer Institute
Volume88
Issue number12
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this